DOJ Targets Gender‑Affirming Care under FDCA and FCA: Scrutinizes Off‑Label Drug Use and False Diagnosis Codes (JSON)

lexblog.com/lib/MPQTP4VVview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "DOJ Targets Gender‑Affirming Care under FDCA and FCA: Scrutinizes Off‑Label Drug Use and False Diagnosis Codes",
    "url": "https://www.lexblog.com/2025/07/16/doj-targets-gender%e2%80%91affirming-care-under-fdca-and-fca-scrutinizes-off%e2%80%91label-drug-use-and-false-diagnosis-codes/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-MPQTP4VV",
        "url": "https://www.lexblog.com/lib/MPQTP4VV/"
    },
    "datePublished": "2025-07-16T21:25:49-04:00",
    "dateModified": "2025-07-16T18:26:29-04:00",
    "author": {
        "@type": "Person",
        "name": "Matthew J. Westbrook, Jonian Rafti, Vinay Kohli, Jason Madden, David Manko"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Proskauer Rose LLP"
    },
    "organizationScope": "at-publication",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.healthcarelawbrief.com/?p=2755",
    "sourceStability": "may-move"
}